Figure 7

Prior immune priming by ⍺-hemolysin increases the therapeutic efficacy of anti-PD-1 antibody. (A) Treatment scheme of (B–D). HLA and the anti-PD-1 antibody were administered by intratumoral injection (IT) and intraperitoneal injection (IP), respectively. (B–D) Body weight changes (B), tumor growth curves (C), and survival curves (D) of EO771 tumor-bearing mice subjected to different groups of treatment. The control group was treated with DPBS (IT) and IgG control (IP, 200 μg) (shown in black, n = 5), the HLA group was treated with HLA (IT, 1 μg) and IgG control (IP, 200 μg) (shown in blue, n = 6), the PD-1 group was treated with DPBS (IT) and anti-PD-1 (IP, 200 μg) (shown in green, n = 6), and the PD-1 + HLA group was treated with HLA (IT, 1 μg) and anti-PD-1 (IP, 200 μg) (shown in red, n = 6). Median survivals are shown in parentheses in (D). The growth curves of each individual tumors were shown in Supplementary Fig. 7. Data are presented as mean ± s.e.m ((B) and (C)). Two-way analysis of variance (ANOVA) with multiple comparisons (C). Log-rank Mantel-Cox test for survival (D). *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant.